National plaintiffs' law firm Berger Montague PCannounces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) (“Telix” or the “Company”) on behalf of investors who purchased Telix securities during the period ofFebruary 21, 2025 through August 28, 2025 (the “Class Period”).
https://mma.prnewswire.com/media/232479/berger_montague.jpg
Investor Deadline: Investors who purchased Telixsecurities during the Class Period may, no later than January 9, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,CLICK HERE.
The Company, based in Melbourne, Australia, focuses on radiopharmaceutical therapies and diagnostics for oncology.
According to the allegations, throughout the Class Period, defendants misrepresented the Company's development progress, including overstating achievements in prostate cancer therapeutics and the reliability of its supply chain and partners. Consequently, statements about the Company's business, operations, and prospects were, according to the complaint, materially false or misleading and unsupported by a reasonable basis. When the truth about the Company's business was disclosed, investors suffered significant losses.
If you are a Telix investor and would like to learn more about this action, CLICK HEREor please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.
About Berger MontagueBerger Montague is one of the nation's preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.
For more information or to discuss your rights, please contact:Andrew AbramowitzSenior CounselBerger Montague(215) 875-3015aabramowitz@bergermontague.com
Caitlin AdorniDirector of Portfolio & Institutional Client Monitoring ServicesBerger Montague(267) 764-4865cadorni@bergermontague.com
https://edge.prnewswire.com/c/img/favicon.png?sn=DC28989&sd=2025-11-19
View original content to download multimedia:https://www.prnewswire.com/news-releases/berger-montague-pc-investigating-claims-on-behalf-of-telix-pharmaceuticals-ltd-nasdaq-tlx-after-class-action-filing-302620591.html
SOURCE Berger Montague
https://rt.newswire.ca/rt.gif?NewsItemId=DC28989&Transmission_Id=202511191251PR_NEWS_USPR_____DC28989&DateId=20251119